Gene-Guided cocktail aims to outsmart tough lymphoma
NCT ID NCT06803693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding drugs tailored to a patient's tumor genetics can improve standard chemotherapy for untreated diffuse large B-cell lymphoma. About 152 adults with intermediate-to-high risk disease will receive either the standard Pola-RCHP regimen or a version with extra targeted agents. The main goal is to see if the personalized combo delays cancer progression or relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone, and genotype-guided targeted agents
What this could lead to
If successful, this could lead to a more personalized treatment approach for DLBCL, potentially improving how long patients stay cancer-free.
What could go wrong
This is a phase 2 trial with only 152 participants, so results are preliminary. The added drugs may increase side effects without clear benefit, and the approach may not work for all genetic subtypes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••